<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d448" origId="Fulvestrant"><sentence id="DrugDDI.d448.s0" origId="s0" text="Fulvestrant is metabolized by CYP 3A4 in vitro."><entity id="DrugDDI.d448.s0.e0" origId="s0.p0" charOffset="0-11" type="drug" text="Fulvestrant"/><entity id="DrugDDI.d448.s0.e1" origId="s0.p3" charOffset="30-33" type="drug" text="CYP"/><pair id="DrugDDI.d448.s0.p0" e1="DrugDDI.d448.s0.e0" e2="DrugDDI.d448.s0.e1" interaction="false"/></sentence><sentence id="DrugDDI.d448.s1" origId="s1" text="Clinical studies of the effect of strong CYP 3A4 inhibitors on the pharmacokinetics of fulvestrant have not been performed."><entity id="DrugDDI.d448.s1.e0" origId="s1.p8" charOffset="87-98" type="drug" text="fulvestrant"/></sentence><sentence id="DrugDDI.d448.s2" origId="s2" text="Carcinogenesis, Mutagenesis and Impairment of Fertility A two-year carcinogenesis study was conducted in female and male rats, at intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days and 10 mg/rat/15 days."/><sentence id="DrugDDI.d448.s3" origId="s3" text="These doses correspond to approximately 1-, 3-, and 5-fold (in females) and 1.3-, 1.3-, and 1.6-fold (in males) the systemic exposure [AUC0-30 days]] achieved in women receiving the recommended dose of 250 mg/month."/><sentence id="DrugDDI.d448.s4" origId="s4" text="An increased incidence of benign ovarian granulosa cell tumors and testicular Leydig cell tumors was evident, in females dosed at 10 mg/rat/15 days and males dosed at 15 mg/rat/30 days, respectively."/><sentence id="DrugDDI.d448.s5" origId="s5" text="Induction of such tumors is consistent with the pharmacology-related endocrine feedback alterations in gonadotropin levels caused by an antiestrogen."><entity id="DrugDDI.d448.s5.e0" origId="s5.p83" charOffset="136-148" type="drug" text="antiestrogen"/></sentence><sentence id="DrugDDI.d448.s6" origId="s6" text="Fulvestrant was not mutagenic or clastogenic in multiple in vitro tests with and without the addition of a mammalian liver metabolic activation factor (bacterial mutation assay in strains of Salmonella typhimurium and Escherichia coli, in vitro cytogenetics study in human lymphocytes, mammalian cell mutation assay in mouse lymphoma cells and in vivo micronucleus test in rat."><entity id="DrugDDI.d448.s6.e0" origId="s6.p84" charOffset="0-11" type="drug" text="Fulvestrant"/><entity id="DrugDDI.d448.s6.e1" origId="s6.p93" charOffset="117-122" type="drug" text="liver"/><pair id="DrugDDI.d448.s6.p0" e1="DrugDDI.d448.s6.e0" e2="DrugDDI.d448.s6.e1" interaction="false"/></sentence><sentence id="DrugDDI.d448.s7" origId="s7" text="In female rats, fulvestrant administered at doses   0.01 mg/kg/day (approximately one-hundredth of the human recommended dose based on body surface area [BSA], for 2 weeks prior to and for 1 week following mating, caused a reduction in fertility and embryonic survival."><entity id="DrugDDI.d448.s7.e0" origId="s7.p109" charOffset="16-27" type="drug" text="fulvestrant"/><entity id="DrugDDI.d448.s7.e1" origId="s7.p120" charOffset="154-157" type="drug" text="BSA"/><pair id="DrugDDI.d448.s7.p0" e1="DrugDDI.d448.s7.e0" e2="DrugDDI.d448.s7.e1" interaction="false"/></sentence><sentence id="DrugDDI.d448.s8" origId="s8" text="No adverse effects on female fertility and embryonic survival were evident in female animals dosed at 0.001 mg/kg/day (approximately one-thousandth of the human dose based on BSA)."><entity id="DrugDDI.d448.s8.e0" origId="s8.p147" charOffset="175-178" type="drug" text="BSA"/></sentence><sentence id="DrugDDI.d448.s9" origId="s9" text="Restoration of female fertility to values similar to controls was evident following a 29-day withdrawal period after dosing at 2 mg/kg/day (twice the human dose based on BSA)."><entity id="DrugDDI.d448.s9.e0" origId="s9.p165" charOffset="170-173" type="drug" text="BSA"/></sentence><sentence id="DrugDDI.d448.s10" origId="s10" text="The effects of fulvestrant on the fertility of female rats appear to be consistent with its anti-estrogenic activity."><entity id="DrugDDI.d448.s10.e0" origId="s10.p168" charOffset="15-26" type="drug" text="fulvestrant"/><entity id="DrugDDI.d448.s10.e1" origId="s10.p175" charOffset="92-108" type="drug" text="anti-estrogenic"/><pair id="DrugDDI.d448.s10.p0" e1="DrugDDI.d448.s10.e0" e2="DrugDDI.d448.s10.e1" interaction="false"/></sentence><sentence id="DrugDDI.d448.s11" origId="s11" text="The potential effects of fulvestrant on the fertility of male animals were not studied but in a 6-month toxicology study, male rats treated with intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days, or 10 mg/rat/15 days fulvestrant showed a loss of spermatozoa from the seminiferous tubules, seminiferous tubular atrophy, and degenerative changes in the epididymides."><entity id="DrugDDI.d448.s11.e0" origId="s11.p177" charOffset="25-36" type="drug" text="fulvestrant"/><entity id="DrugDDI.d448.s11.e1" origId="s11.p197" charOffset="226-237" type="drug" text="fulvestrant"/><pair id="DrugDDI.d448.s11.p0" e1="DrugDDI.d448.s11.e0" e2="DrugDDI.d448.s11.e1" interaction="false"/></sentence><sentence id="DrugDDI.d448.s12" origId="s12" text="Changes in the testes and epididymides had not recovered 20 weeks after cessation of dosing."/><sentence id="DrugDDI.d448.s13" origId="s13" text="These fulvestrant doses correspond to approximately 2-, 3-, and 3-fold the systemic exposure [AUC0-30 days] achieved in women."><entity id="DrugDDI.d448.s13.e0" origId="s13.p216" charOffset="6-17" type="drug" text="fulvestrant"/></sentence><sentence id="DrugDDI.d448.s14" origId="s14" text="Pregnancy Pregnancy Category D: ."/><sentence id="DrugDDI.d448.s15" origId="s15" text="In studies in female rats at doses   0.01 mg/kg/day (IM;"/><sentence id="DrugDDI.d448.s16" origId="s16" text="approximately one-hundredth of the human recommended dose based on body surface area [BSA]), fulvestrant caused a reversible reduction in female fertility, as well as effects on embryo/fetal development consistent with its anti-estrogenic activity."><entity id="DrugDDI.d448.s16.e0" origId="s16.p241" charOffset="86-89" type="drug" text="BSA"/><entity id="DrugDDI.d448.s16.e1" origId="s16.p244" charOffset="93-104" type="drug" text="fulvestrant"/><entity id="DrugDDI.d448.s16.e2" origId="s16.p252" charOffset="223-239" type="drug" text="anti-estrogenic"/><pair id="DrugDDI.d448.s16.p0" e1="DrugDDI.d448.s16.e0" e2="DrugDDI.d448.s16.e1" interaction="false"/><pair id="DrugDDI.d448.s16.p1" e1="DrugDDI.d448.s16.e0" e2="DrugDDI.d448.s16.e2" interaction="false"/><pair id="DrugDDI.d448.s16.p2" e1="DrugDDI.d448.s16.e1" e2="DrugDDI.d448.s16.e2" interaction="false"/></sentence><sentence id="DrugDDI.d448.s17" origId="s17" text="Fulvestrant caused an increased incidence of fetal abnormalities in rats (tarsal flexure of the hind paw at 2 mg/kg/day IM;"><entity id="DrugDDI.d448.s17.e0" origId="s17.p253" charOffset="0-11" type="drug" text="Fulvestrant"/></sentence><sentence id="DrugDDI.d448.s18" origId="s18" text="twice the human dose on BSA) and non-ossification of the odontoid and ventral tubercle of the first cervical vertebra at doses   0.1 mg/kg/day IM (approximately one-tenth of the human dose on BSA) when administered during the period of organogenesis."><entity id="DrugDDI.d448.s18.e0" origId="s18.p267" charOffset="24-27" type="drug" text="BSA"/><entity id="DrugDDI.d448.s18.e1" origId="s18.p281" charOffset="192-195" type="drug" text="BSA"/><pair id="DrugDDI.d448.s18.p0" e1="DrugDDI.d448.s18.e0" e2="DrugDDI.d448.s18.e1" interaction="false"/></sentence><sentence id="DrugDDI.d448.s19" origId="s19" text="Rabbits failed to maintain pregnancy when dosed with 1 mg/kg/day fulvestrant IM (twice the human dose on BSA) during the period of organogenesis."><entity id="DrugDDI.d448.s19.e0" origId="s19.p296" charOffset="65-76" type="drug" text="fulvestrant"/><entity id="DrugDDI.d448.s19.e1" origId="s19.p300" charOffset="105-108" type="drug" text="BSA"/><pair id="DrugDDI.d448.s19.p0" e1="DrugDDI.d448.s19.e0" e2="DrugDDI.d448.s19.e1" interaction="false"/></sentence><sentence id="DrugDDI.d448.s20" origId="s20" text="Further, in rabbits dosed at 0.25 mg/kg/day (about one-half the human dose on BSA), increases in placental weight and post-implantation loss were observed but, there were no observed effects on fetal development."><entity id="DrugDDI.d448.s20.e0" origId="s20.p313" charOffset="78-81" type="drug" text="BSA"/></sentence><sentence id="DrugDDI.d448.s21" origId="s21" text="Fulvestrant was associated with an increased incidence of fetal variations in rabbits (backwards displacement of the pelvic girdle, and 27 pre-sacral vertebrae at 0.25 mg/kg/day IM;"><entity id="DrugDDI.d448.s21.e0" origId="s21.p328" charOffset="0-11" type="drug" text="Fulvestrant"/></sentence><sentence id="DrugDDI.d448.s22" origId="s22" text="one-half the human dose on BSA) when administered during the period of organogenesis."><entity id="DrugDDI.d448.s22.e0" origId="s22.p345" charOffset="27-30" type="drug" text="BSA"/></sentence><sentence id="DrugDDI.d448.s23" origId="s23" text="Because pregnancy could not be maintained in the rabbit following doses of fulvestrant of 1 mg/kg/day and above, this study was inadequate to fully define the possible adverse effects on fetal development at clinically relevant exposures."><entity id="DrugDDI.d448.s23.e0" origId="s23.p360" charOffset="75-86" type="drug" text="fulvestrant"/></sentence><sentence id="DrugDDI.d448.s24" origId="s24" text="Nursing Mothers Fulvestrant is found in rat milk at levels significantly higher (approximately 12-fold) than plasma after administration of 2 mg/kg."><entity id="DrugDDI.d448.s24.e0" origId="s24.p373" charOffset="16-27" type="drug" text="Fulvestrant"/></sentence><sentence id="DrugDDI.d448.s25" origId="s25" text="Drug exposure in rodent pups from fulvestrant-treated lactating dams was estimated as 10% of the administered dose."><entity id="DrugDDI.d448.s25.e0" origId="s25.p387" charOffset="34-45" type="drug" text="fulvestrant"/></sentence><sentence id="DrugDDI.d448.s26" origId="s26" text="It is not known if fulvestrant is excreted in human milk."><entity id="DrugDDI.d448.s26.e0" origId="s26.p396" charOffset="19-30" type="drug" text="fulvestrant"/></sentence><sentence id="DrugDDI.d448.s27" origId="s27" text="Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions from FASLODEX in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother."><entity id="DrugDDI.d448.s27.e0" origId="s27.p401" charOffset="13-18" type="drug" text="drugs"/><entity id="DrugDDI.d448.s27.e1" origId="s27.p408" charOffset="111-119" type="drug" text="FASLODEX"/><entity id="DrugDDI.d448.s27.e2" origId="s27.p419" charOffset="219-223" type="drug" text="drug"/><entity id="DrugDDI.d448.s27.e3" origId="s27.p423" charOffset="266-270" type="drug" text="drug"/><pair id="DrugDDI.d448.s27.p0" e1="DrugDDI.d448.s27.e0" e2="DrugDDI.d448.s27.e1" interaction="false"/><pair id="DrugDDI.d448.s27.p1" e1="DrugDDI.d448.s27.e0" e2="DrugDDI.d448.s27.e2" interaction="false"/><pair id="DrugDDI.d448.s27.p2" e1="DrugDDI.d448.s27.e0" e2="DrugDDI.d448.s27.e3" interaction="false"/><pair id="DrugDDI.d448.s27.p3" e1="DrugDDI.d448.s27.e1" e2="DrugDDI.d448.s27.e2" interaction="false"/><pair id="DrugDDI.d448.s27.p4" e1="DrugDDI.d448.s27.e1" e2="DrugDDI.d448.s27.e3" interaction="false"/><pair id="DrugDDI.d448.s27.p5" e1="DrugDDI.d448.s27.e2" e2="DrugDDI.d448.s27.e3" interaction="false"/></sentence><sentence id="DrugDDI.d448.s28" origId="s28" text="Pediatric Use The safety and efficacy of FASLODEX in pediatric patients have not been established."><entity id="DrugDDI.d448.s28.e0" origId="s28.p425" charOffset="0-9" type="drug" text="Pediatric"/><entity id="DrugDDI.d448.s28.e1" origId="s28.p430" charOffset="41-49" type="drug" text="FASLODEX"/><pair id="DrugDDI.d448.s28.p0" e1="DrugDDI.d448.s28.e0" e2="DrugDDI.d448.s28.e1" interaction="false"/></sentence><sentence id="DrugDDI.d448.s29" origId="s29" text="Geriatric Use When tumor response was considered by age, objective responses were seen in 24% and 22% of patients under 65 years of age and in 16% and 11% of patients 65 years of age and older, who were treated with FASLODEX in the European and North American trials, respectively."><entity id="DrugDDI.d448.s29.e0" origId="s29.p462" charOffset="216-224" type="drug" text="FASLODEX"/></sentence></document>